img

Global Cholera Vaccine (Oral Route) Industry Research Report, Growth Trends and Competitive Analysis 2024-2034


Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare

Publisher : MRA | Format : PDF

Global Cholera Vaccine (Oral Route) Industry Research Report, Growth Trends and Competitive Analysis 2024-2034

The global Cholera Vaccine (Oral Route) market size was US$ million in 2022 and is forecast to a readjusted size of US$ million by 2034 with a CAGR of % during the forecast period 2024-2034.
The United States market for Cholera Vaccine (Oral Route) is estimated to increase from $ million in 2024 to reach $ million by 2034, at a CAGR of % during the forecast period of 2024 through 2034.
The China market for Cholera Vaccine (Oral Route) is estimated to increase from $ million in 2024 to reach $ million by 2034, at a CAGR of % during the forecast period of 2024 through 2034.
The Europe market for Cholera Vaccine (Oral Route) is estimated to increase from $ million in 2024 to reach $ million by 2034, at a CAGR of % during the forecast period of 2024 through 2034..
The global key manufacturers of Cholera Vaccine (Oral Route) include PaxVax, Sanofi, Valneva and EuBiologics, etc. In 2022, the global top five players hold a share approximately % in sales volume, and in term of revenue of Cholera Vaccine (Oral Route), the top five companies hold a share nearly %.
In terms of sales (consumption) side, this report focuses on the sales of Cholera Vaccine (Oral Route) by regions (Countries), company, by type and by type. from 2018 to 2024 and forecast to 2034.
The global Cholera Vaccine (Oral Route) market is thoroughly, accurately, and comprehensively assessed in the report with a large focus on market dynamics, market competition, regional growth, segmental analysis, and key growth strategies. Buyers of the report will have access to verified market figures, including global market size in terms of revenue and volume. As part of sales analysis, the authors of the report have provided reliable estimations and calculations for global revenue and sales by type segment of the global Cholera Vaccine (Oral Route) market. These figures have been provided in terms of both revenue and sales for the period 2018-2034. Additionally, the report provides accurate figures for sales by region in terms of revenue as well as volume for the same period.



By Company


PaxVax
Sanofi
Valneva
EuBiologics
By Type
Shanchol
Dukoral
Vaxchora
Others
By Application
Hospital
Research & Academic Laboratories
Pharmaceutical & Biotechnology Companies
Others
Sales by Region
North America
U.S.
Canada
China
APAC (excluding China)
Japan
South Korea
China Taiwan
Southeast Asia
Europe
Germany
France
U.K.
Italy
Russia
Middle East, Africa, Latin America
Brazil
Mexico
Turkey
Israel
GCC Countries

Chapter Outline


Chapter 1Introduces the report scope of the report, executive summary of different market segments (by type and by application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2Sales (consumption), revenue of Cholera Vaccine (Oral Route) in global, regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 3Detailed analysis of Cholera Vaccine (Oral Route) manufacturers competitive landscape, price, sales, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4Provides the analysis of various market segments by type, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5Provides the analysis of various market segments by application, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6North America by company, by type, by application and by country, sales, and revenue for each segment.
Chapter 7Europe by company, by type, by application and by country, sales, and revenue for each segment.
Chapter 8China by company, by type and by application, sales, and revenue for each segment.
Chapter 9APAC (excluding China) by company, by type, by application and by region, sales, and revenue for each segment.
Chapter 10Middle East, Africa, and Latin America by company, by type, by application and by country, sales, and revenue for each segment.
Chapter 11Provides profiles of key manufacturers, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Cholera Vaccine (Oral Route) sales, revenue, price, gross margin, and recent development, etc.
Chapter 12Analysis of industrial chain, sales channel, key raw materials, distributors, and customers.
Chapter 13Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 14The main points and conclusions of the report.

Table of Content

1 Report Overview
1.1 Cholera Vaccine (Oral Route) Definition
1.2 Market by Type
1.2.1 Global Cholera Vaccine (Oral Route) Market Size Growth Rate by Type, 2018 VS 2022 VS 2034
1.2.2 Shanchol
1.2.3 Dukoral
1.2.4 Vaxchora
1.2.5 Others
1.3 Market Segment by Application
1.3.1 Global Cholera Vaccine (Oral Route) Market Size Growth Rate by Application, 2018 VS 2022 VS 2034
1.3.2 Hospital
1.3.3 Research & Academic Laboratories
1.3.4 Pharmaceutical & Biotechnology Companies
1.3.5 Others
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Cholera Vaccine (Oral Route) Sales
2.1 Global Cholera Vaccine (Oral Route) Revenue Estimates and Forecasts 2018-2034
2.2 Global Cholera Vaccine (Oral Route) Revenue by Region: 2018 VS 2022 VS 2034
2.3 Global Cholera Vaccine (Oral Route) Revenue by Region
2.3.1 Global Cholera Vaccine (Oral Route) Revenue by Region (2018-2024)
2.3.2 Global Cholera Vaccine (Oral Route) Revenue by Region (2024-2034)
2.4 Global Cholera Vaccine (Oral Route) Sales Quantity Estimates and Forecasts 2018-2034
2.5 Global Cholera Vaccine (Oral Route) Sales Quantity by Region: 2018 VS 2022 VS 2034
2.6 Global Cholera Vaccine (Oral Route) Sales Quantity by Region
2.6.1 Global Cholera Vaccine (Oral Route) Sales Quantity by Region (2018-2024)
2.6.2 Global Cholera Vaccine (Oral Route) Sales Quantity by Region (2024-2034)
2.7 North America
2.8 Europe
2.9 China
2.10 APAC (excluding China)
2.11 Middle East, Africa and Latin America
3 Competition by Manufacturers
3.1 Global Cholera Vaccine (Oral Route) Sales Quantity by Manufacturers
3.1.1 Global Cholera Vaccine (Oral Route) Sales Quantity by Manufacturers (2018-2024)
3.1.2 Global Cholera Vaccine (Oral Route) Sales Quantity Share by Manufacturers (2018-2024)
3.1.3 Global Top 10 and Top 5 Companies by Cholera Vaccine (Oral Route) Sales in 2022
3.2 Global Cholera Vaccine (Oral Route) Revenue by Manufacturers
3.2.1 Global Cholera Vaccine (Oral Route) Revenue by Manufacturers (2018-2024)
3.2.2 Global Cholera Vaccine (Oral Route) Revenue Share by Manufacturers (2018-2024)
3.2.3 Global Top 10 and Top 5 Companies by Cholera Vaccine (Oral Route) Revenue in 2022
3.3 Global Cholera Vaccine (Oral Route) Sales Price by Manufacturers
3.4 Global Key Players of Cholera Vaccine (Oral Route), Industry Ranking, 2021 VS 2022
3.5 Analysis of Competitive Landscape
3.5.1 Manufacturers Market Concentration Ratio (CR5 and HHI)
3.5.2 Global Cholera Vaccine (Oral Route) Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.6 Global Key Manufacturers of Cholera Vaccine (Oral Route), Manufacturing Base Distribution and Headquarters
3.7 Global Key Manufacturers of Cholera Vaccine (Oral Route), Product Offered and Application
3.8 Global Key Manufacturers of Cholera Vaccine (Oral Route), Date of Enter into This Industry
3.9 Mergers & Acquisitions, Expansion Plans
4 Estimates and Forecasts by Type
4.1 Global Cholera Vaccine (Oral Route) Sales Quantity by Type
4.1.1 Global Cholera Vaccine (Oral Route) Historical Sales Quantity by Type (2018-2024)
4.1.2 Global Cholera Vaccine (Oral Route) Forecasted Sales Quantity by Type (2024-2034)
4.1.3 Global Cholera Vaccine (Oral Route) Sales Quantity Market Share by Type (2018-2034)
4.2 Global Cholera Vaccine (Oral Route) Revenue by Type
4.2.1 Global Cholera Vaccine (Oral Route) Historical Revenue by Type (2018-2024)
4.2.2 Global Cholera Vaccine (Oral Route) Forecasted Revenue by Type (2024-2034)
4.2.3 Global Cholera Vaccine (Oral Route) Revenue Market Share by Type (2018-2034)
4.3 Global Cholera Vaccine (Oral Route) Price by Type
4.3.1 Global Cholera Vaccine (Oral Route) Price by Type (2018-2024)
4.3.2 Global Cholera Vaccine (Oral Route) Price Forecast by Type (2024-2034)
5 Market Size by Application
5.1 Global Cholera Vaccine (Oral Route) Sales Quantity by Application
5.1.1 Global Cholera Vaccine (Oral Route) Historical Sales Quantity by Application (2018-2024)
5.1.2 Global Cholera Vaccine (Oral Route) Forecasted Sales Quantity by Application (2024-2034)
5.1.3 Global Cholera Vaccine (Oral Route) Sales Quantity Market Share by Application (2018-2034)
5.2 Global Cholera Vaccine (Oral Route) Revenue by Application
5.2.1 Global Cholera Vaccine (Oral Route) Historical Revenue by Application (2018-2024)
5.2.2 Global Cholera Vaccine (Oral Route) Forecasted Revenue by Application (2024-2034)
5.2.3 Global Cholera Vaccine (Oral Route) Revenue Market Share by Application (2018-2034)
5.3 Global Cholera Vaccine (Oral Route) Price by Application
5.3.1 Global Cholera Vaccine (Oral Route) Price by Application (2018-2024)
5.3.2 Global Cholera Vaccine (Oral Route) Price Forecast by Application (2024-2034)
6 North America
6.1 North America Cholera Vaccine (Oral Route) Sales by Company
6.1.1 North America Cholera Vaccine (Oral Route) Revenue by Company (2018-2024)
6.1.2 North America Cholera Vaccine (Oral Route) Sales Quantity by Company (2018-2024)
6.2 North America Cholera Vaccine (Oral Route) Market Size by Type
6.2.1 North America Cholera Vaccine (Oral Route) Sales Quantity by Type (2018-2034)
6.2.2 North America Cholera Vaccine (Oral Route) Revenue by Type (2018-2034)
6.3 North America Cholera Vaccine (Oral Route) Market Size by Application
6.3.1 North America Cholera Vaccine (Oral Route) Sales Quantity by Application (2018-2034)
6.3.2 North America Cholera Vaccine (Oral Route) Revenue by Application (2018-2034)
6.4 North America Cholera Vaccine (Oral Route) Market Size by Country
6.4.1 North America Cholera Vaccine (Oral Route) Revenue by Country: 2018 VS 2022 VS 2034
6.4.2 North America Cholera Vaccine (Oral Route) Revenue by Country (2018-2034)
6.4.3 North America Cholera Vaccine (Oral Route) Sales Quantity by Country (2018-2034)
6.4.4 U.S.
6.4.5 Canada
7 Europe
7.1 Europe Cholera Vaccine (Oral Route) Sales by Company
7.1.1 Europe Cholera Vaccine (Oral Route) Sales Quantity by Company (2018-2024)
7.1.2 Europe Cholera Vaccine (Oral Route) Revenue by Company (2018-2024)
7.2 Europe Cholera Vaccine (Oral Route) Market Size by Type
7.2.1 Europe Cholera Vaccine (Oral Route) Sales Quantity by Type (2018-2034)
7.2.2 Europe Cholera Vaccine (Oral Route) Revenue by Type (2018-2034)
7.3 Europe Cholera Vaccine (Oral Route) Market Size by Application
7.3.1 Europe Cholera Vaccine (Oral Route) Sales Quantity by Application (2018-2034)
7.3.2 Europe Cholera Vaccine (Oral Route) Revenue by Application (2018-2034)
7.4 Europe Cholera Vaccine (Oral Route) Market Size by Country
7.4.1 Europe Cholera Vaccine (Oral Route) Revenue by Country: 2018 VS 2022 VS 2034
7.4.2 Europe Cholera Vaccine (Oral Route) Revenue by Country (2018-2034)
7.4.3 Europe Cholera Vaccine (Oral Route) Sales Quantity by Country (2018-2034)
7.4.4 Germany
7.4.5 France
7.4.6 U.K.
7.4.7 Italy
7.4.8 Russia
8 China
8.1 China Cholera Vaccine (Oral Route) Sales by Company
8.1.1 China Cholera Vaccine (Oral Route) Sales Quantity by Company (2018-2024)
8.1.2 China Cholera Vaccine (Oral Route) Revenue by Company (2018-2024)
8.2 China Cholera Vaccine (Oral Route) Market Size by Type
8.2.1 China Cholera Vaccine (Oral Route) Sales Quantity by Type (2018-2034)
8.2.2 China Cholera Vaccine (Oral Route) Revenue by Type (2018-2034)
8.3 China Cholera Vaccine (Oral Route) Market Size by Application
8.3.1 China Cholera Vaccine (Oral Route) Sales Quantity by Application (2018-2034)
8.3.2 China Cholera Vaccine (Oral Route) Revenue by Application (2018-2034)
9 APAC (excluding China)
9.1 APAC Cholera Vaccine (Oral Route) Sales by Company
9.1.1 APAC Cholera Vaccine (Oral Route) Sales Quantity by Company (2018-2024)
9.1.2 APAC Cholera Vaccine (Oral Route) Revenue by Company (2018-2024)
9.2 APAC Cholera Vaccine (Oral Route) Market Size by Type
9.2.1 APAC Cholera Vaccine (Oral Route) Sales Quantity by Type (2018-2034)
9.2.2 APAC Cholera Vaccine (Oral Route) Revenue by Type (2018-2034)
9.3 APAC Cholera Vaccine (Oral Route) Market Size by Application
9.3.1 APAC Cholera Vaccine (Oral Route) Sales Quantity by Application (2018-2034)
9.3.2 APAC Cholera Vaccine (Oral Route) Revenue by Application (2018-2034)
9.4 APAC Cholera Vaccine (Oral Route) Market Size by Region
9.4.1 APAC Cholera Vaccine (Oral Route) Revenue by Region: 2018 VS 2022 VS 2034
9.4.2 APAC Cholera Vaccine (Oral Route) Revenue by Region (2018-2034)
9.4.3 APAC Cholera Vaccine (Oral Route) Sales Quantity by Region (2018-2034)
9.4.4 Japan
9.4.5 South Korea
9.4.6 China Taiwan
9.4.7 Southeast Asia
9.4.8 India
10 Middle East, Africa and Latin America
10.1 Middle East, Africa and Latin America Cholera Vaccine (Oral Route) Sales by Company
10.1.1 Middle East, Africa and Latin America Cholera Vaccine (Oral Route) Sales Quantity by Company (2018-2024)
10.1.2 Middle East, Africa and Latin America Cholera Vaccine (Oral Route) Revenue by Company (2018-2024)
10.2 Middle East, Africa and Latin America Cholera Vaccine (Oral Route) Market Size by Type
10.2.1 Middle East, Africa and Latin America Cholera Vaccine (Oral Route) Sales Quantity by Type (2018-2034)
10.2.2 Middle East, Africa and Latin America Cholera Vaccine (Oral Route) Revenue by Type (2018-2034)
10.3 Middle East, Africa and Latin America Cholera Vaccine (Oral Route) Market Size by Application
10.3.1 Middle East, Africa and Latin America Cholera Vaccine (Oral Route) Sales Quantity by Application (2018-2034)
10.3.2 Middle East, Africa and Latin America Cholera Vaccine (Oral Route) Revenue by Application (2018-2034)
10.4 Middle East, Africa and Latin America Cholera Vaccine (Oral Route) Market Size by Country
10.4.1 Middle East, Africa and Latin America Cholera Vaccine (Oral Route) Revenue by Country: 2018 VS 2022 VS 2034
10.4.2 Middle East, Africa and Latin America Cholera Vaccine (Oral Route) Revenue by Country (2018-2034)
10.4.3 Middle East, Africa and Latin America Cholera Vaccine (Oral Route) Sales Quantity by Country (2018-2034)
10.4.4 Brazil
10.4.5 Mexico
10.4.6 Turkey
10.4.7 Israel
10.4.8 GCC Countries
11 Company Profiles
11.1 PaxVax
11.1.1 PaxVax Company Information
11.1.2 PaxVax Overview
11.1.3 PaxVax Cholera Vaccine (Oral Route) Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2024)
11.1.4 PaxVax Cholera Vaccine (Oral Route) Products and Services
11.1.5 PaxVax Cholera Vaccine (Oral Route) SWOT Analysis
11.1.6 PaxVax Recent Developments
11.2 Sanofi
11.2.1 Sanofi Company Information
11.2.2 Sanofi Overview
11.2.3 Sanofi Cholera Vaccine (Oral Route) Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2024)
11.2.4 Sanofi Cholera Vaccine (Oral Route) Products and Services
11.2.5 Sanofi Cholera Vaccine (Oral Route) SWOT Analysis
11.2.6 Sanofi Recent Developments
11.3 Valneva
11.3.1 Valneva Company Information
11.3.2 Valneva Overview
11.3.3 Valneva Cholera Vaccine (Oral Route) Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2024)
11.3.4 Valneva Cholera Vaccine (Oral Route) Products and Services
11.3.5 Valneva Cholera Vaccine (Oral Route) SWOT Analysis
11.3.6 Valneva Recent Developments
11.4 EuBiologics
11.4.1 EuBiologics Company Information
11.4.2 EuBiologics Overview
11.4.3 EuBiologics Cholera Vaccine (Oral Route) Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2024)
11.4.4 EuBiologics Cholera Vaccine (Oral Route) Products and Services
11.4.5 EuBiologics Cholera Vaccine (Oral Route) SWOT Analysis
11.4.6 EuBiologics Recent Developments
12 Value Chain and Sales Channels Analysis
12.1 Cholera Vaccine (Oral Route) Value Chain Analysis
12.2 Cholera Vaccine (Oral Route) Key Raw Materials
12.2.1 Key Raw Materials
12.2.2 Raw Materials Key Suppliers
12.3 Cholera Vaccine (Oral Route) Production Mode & Process
12.4 Cholera Vaccine (Oral Route) Sales and Marketing
12.4.1 Cholera Vaccine (Oral Route) Sales Channels
12.4.2 Cholera Vaccine (Oral Route) Distributors
12.5 Cholera Vaccine (Oral Route) Customers
13 Market Dynamics
13.1 Cholera Vaccine (Oral Route) Industry Trends
13.2 Cholera Vaccine (Oral Route) Market Drivers
13.3 Cholera Vaccine (Oral Route) Market Challenges
13.4 Cholera Vaccine (Oral Route) Market Restraints
14 Key Findings
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Author Details
15.3 Disclaimer

List of Figure

List of Tables
Table 1. Global Cholera Vaccine (Oral Route) Market Size Growth Rate (CAGR) by Type, 2018 VS 2022 VS 2034 (US$ Million)
Table 2. Major Manufacturers of Shanchol
Table 3. Major Manufacturers of Dukoral
Table 4. Major Manufacturers of Vaxchora
Table 5. Major Manufacturers of Others
Table 6. Global Cholera Vaccine (Oral Route) Market Size Growth Rate (CAGR) by Application, 2018 VS 2022 VS 2034 (US$ Million)
Table 7. Global Cholera Vaccine (Oral Route) Revenue by Region: 2018 VS 2022 VS 2034 (US$ Million)
Table 8. Global Cholera Vaccine (Oral Route) Revenue by Region (2018-2024) & (US$ Million)
Table 9. Global Cholera Vaccine (Oral Route) Revenue Market Share by Region (2018-2024)
Table 10. Global Cholera Vaccine (Oral Route) Revenue by Region (2024-2034) & (US$ Million)
Table 11. Global Cholera Vaccine (Oral Route) Revenue Market Share by Region (2024-2034)
Table 12. Global Cholera Vaccine (Oral Route) Sales Quantity by Region: 2018 VS 2022 VS 2034 (K Units)
Table 13. Global Cholera Vaccine (Oral Route) Sales by Region (2018-2024) & (K Units)
Table 14. Global Cholera Vaccine (Oral Route) Sales Market Share by Region (2018-2024)
Table 15. Global Cholera Vaccine (Oral Route) Sales by Region (2024-2034) & (K Units)
Table 16. Global Cholera Vaccine (Oral Route) Sales Market Share by Region (2024-2034)
Table 17. Global Cholera Vaccine (Oral Route) Sales Quantity by Manufacturers (2018-2024) & (K Units)
Table 18. Global Cholera Vaccine (Oral Route) Sales Quantity Share by Manufacturers (2018-2024)
Table 19. Global Cholera Vaccine (Oral Route) Revenue by Manufacturers (2018-2024) & (US$ Million)
Table 20. Global Cholera Vaccine (Oral Route) Revenue Share by Manufacturers (2018-2024)
Table 21. Global Cholera Vaccine (Oral Route) Price by Manufacturers 2018-2024 (USD/Unit)
Table 22. Global Key Players of Cholera Vaccine (Oral Route), Industry Ranking, 2021 VS 2022
Table 23. Global Cholera Vaccine (Oral Route) Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 24. Global Cholera Vaccine (Oral Route) by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Cholera Vaccine (Oral Route) as of 2022)
Table 25. Global Key Manufacturers of Cholera Vaccine (Oral Route), Manufacturing Base Distribution and Headquarters
Table 26. Global Key Manufacturers of Cholera Vaccine (Oral Route), Product Offered and Application
Table 27. Global Key Manufacturers of Cholera Vaccine (Oral Route), Date of Enter into This Industry
Table 28. Mergers & Acquisitions, Expansion Plans
Table 29. Global Cholera Vaccine (Oral Route) Sales Quantity by Type (2018-2024) & (K Units)
Table 30. Global Cholera Vaccine (Oral Route) Sales Quantity by Type (2024-2034) & (K Units)
Table 31. Global Cholera Vaccine (Oral Route) Sales Quantity Share by Type (2018-2024)
Table 32. Global Cholera Vaccine (Oral Route) Sales Quantity Share by Type (2024-2034)
Table 33. Global Cholera Vaccine (Oral Route) Revenue by Type (2018-2024) & (US$ Million)
Table 34. Global Cholera Vaccine (Oral Route) Revenue by Type (2024-2034) & (US$ Million)
Table 35. Global Cholera Vaccine (Oral Route) Revenue Share by Type (2018-2024)
Table 36. Global Cholera Vaccine (Oral Route) Revenue Share by Type (2024-2034)
Table 37. Cholera Vaccine (Oral Route) Price by Type (2018-2024) & (USD/Unit)
Table 38. Global Cholera Vaccine (Oral Route) Price Forecast by Type (2024-2034) & (USD/Unit)
Table 39. Global Cholera Vaccine (Oral Route) Sales Quantity by Application (2018-2024) & (K Units)
Table 40. Global Cholera Vaccine (Oral Route) Sales Quantity by Application (2024-2034) & (K Units)
Table 41. Global Cholera Vaccine (Oral Route) Sales Quantity Share by Application (2018-2024)
Table 42. Global Cholera Vaccine (Oral Route) Sales Quantity Share by Application (2024-2034)
Table 43. Global Cholera Vaccine (Oral Route) Revenue by Application (2018-2024) & (US$ Million)
Table 44. Global Cholera Vaccine (Oral Route) Revenue by Application (2024-2034) & (US$ Million)
Table 45. Global Cholera Vaccine (Oral Route) Revenue Share by Application (2018-2024)
Table 46. Global Cholera Vaccine (Oral Route) Revenue Share by Application (2024-2034)
Table 47. Cholera Vaccine (Oral Route) Price by Application (2018-2024) & (USD/Unit)
Table 48. Global Cholera Vaccine (Oral Route) Price Forecast by Application (2024-2034) & (USD/Unit)
Table 49. North America Cholera Vaccine (Oral Route) Revenue by Company (2018-2024) & (US$ Million)
Table 50. North America Cholera Vaccine (Oral Route) Sales Quantity by Company (2018-2024) & (K Units)
Table 51. North America Cholera Vaccine (Oral Route) Sales Quantity by Type (2018-2024) & (K Units)
Table 52. North America Cholera Vaccine (Oral Route) Sales Quantity by Type (2024-2034) & (K Units)
Table 53. North America Cholera Vaccine (Oral Route) Revenue by Type (2018-2024) & (US$ Million)
Table 54. North America Cholera Vaccine (Oral Route) Revenue by Type (2024-2034) & (US$ Million)
Table 55. North America Cholera Vaccine (Oral Route) Sales Quantity by Application (2018-2024) & (K Units)
Table 56. North America Cholera Vaccine (Oral Route) Sales Quantity by Application (2024-2034) & (K Units)
Table 57. North America Cholera Vaccine (Oral Route) Revenue by Application (2018-2024) & (US$ Million)
Table 58. North America Cholera Vaccine (Oral Route) Revenue by Application (2024-2034) & (US$ Million)
Table 59. North America Cholera Vaccine (Oral Route) Revenue by Country: 2018 VS 2022 VS 2034 (US$ Million)
Table 60. North America Cholera Vaccine (Oral Route) Revenue by Country (2018-2024) & (US$ Million)
Table 61. North America Cholera Vaccine (Oral Route) Revenue by Country (2024-2034) & (US$ Million)
Table 62. North America Cholera Vaccine (Oral Route) Sales Quantity by Country (2018-2024) & (K Units)
Table 63. North America Cholera Vaccine (Oral Route) Sales Quantity by Country (2024-2034) & (K Units)
Table 64. Europe Cholera Vaccine (Oral Route) Sales Quantity by Company (2018-2024) & (K Units)
Table 65. Europe Cholera Vaccine (Oral Route) Revenue by Company (2018-2024) & (US$ Million)
Table 66. Europe Cholera Vaccine (Oral Route) Sales Quantity by Type (2018-2024) & (K Units)
Table 67. Europe Cholera Vaccine (Oral Route) Sales Quantity by Type (2024-2034) & (K Units)
Table 68. Europe Cholera Vaccine (Oral Route) Revenue by Type (2018-2024) & (US$ Million)
Table 69. Europe Cholera Vaccine (Oral Route) Revenue by Type (2024-2034) & (US$ Million)
Table 70. Europe Cholera Vaccine (Oral Route) Sales Quantity by Application (2018-2024) & (K Units)
Table 71. Europe Cholera Vaccine (Oral Route) Sales Quantity by Application (2024-2034) & (K Units)
Table 72. Europe Cholera Vaccine (Oral Route) Revenue by Application (2018-2024) & (US$ Million)
Table 73. Europe Cholera Vaccine (Oral Route) Revenue by Application (2024-2034) & (US$ Million)
Table 74. Europe Cholera Vaccine (Oral Route) Revenue by Country: 2018 VS 2022 VS 2034 (US$ Million)
Table 75. Europe Cholera Vaccine (Oral Route) Revenue by Country (2018-2024) & (US$ Million)
Table 76. Europe Cholera Vaccine (Oral Route) Revenue by Country (2024-2034) & (US$ Million)
Table 77. Europe Cholera Vaccine (Oral Route) Sales Quantity by Country (2018-2024) & (K Units)
Table 78. Europe Cholera Vaccine (Oral Route) Sales Quantity by Country (2024-2034) & (K Units)
Table 79. China Cholera Vaccine (Oral Route) Sales Quantity by Company (2018-2024) & (K Units)
Table 80. China Cholera Vaccine (Oral Route) Revenue by Company (2018-2024) & (US$ Million)
Table 81. China Cholera Vaccine (Oral Route) Sales Quantity by Type (2018-2024) & (K Units)
Table 82. China Cholera Vaccine (Oral Route) Sales Quantity by Type (2024-2034) & (K Units)
Table 83. China Cholera Vaccine (Oral Route) Revenue by Type (2018-2024) & (US$ Million)
Table 84. China Cholera Vaccine (Oral Route) Revenue by Type (2024-2034) & (US$ Million)
Table 85. China Cholera Vaccine (Oral Route) Sales Quantity by Application (2018-2024) & (K Units)
Table 86. China Cholera Vaccine (Oral Route) Sales Quantity by Application (2024-2034) & (K Units)
Table 87. China Cholera Vaccine (Oral Route) Revenue by Application (2018-2024) & (US$ Million)
Table 88. China Cholera Vaccine (Oral Route) Revenue by Application (2024-2034) & (US$ Million)
Table 89. APAC Cholera Vaccine (Oral Route) Sales Quantity by Company (2018-2024) & (K Units)
Table 90. APAC Cholera Vaccine (Oral Route) Revenue by Company (2018-2024) & (US$ Million)
Table 91. APAC Cholera Vaccine (Oral Route) Sales Quantity by Type (2018-2024) & (K Units)
Table 92. APAC Cholera Vaccine (Oral Route) Sales Quantity by Type (2024-2034) & (K Units)
Table 93. APAC Cholera Vaccine (Oral Route) Revenue by Type (2018-2024) & (US$ Million)
Table 94. APAC Cholera Vaccine (Oral Route) Revenue by Type (2024-2034) & (US$ Million)
Table 95. APAC Cholera Vaccine (Oral Route) Sales Quantity by Application (2018-2024) & (K Units)
Table 96. APAC Cholera Vaccine (Oral Route) Sales Quantity by Application (2024-2034) & (K Units)
Table 97. APAC Cholera Vaccine (Oral Route) Revenue by Application (2018-2024) & (US$ Million)
Table 98. APAC Cholera Vaccine (Oral Route) Revenue by Application (2024-2034) & (US$ Million)
Table 99. APAC Cholera Vaccine (Oral Route) Revenue by Region: 2018 VS 2022 VS 2034 (US$ Million)
Table 100. APAC Cholera Vaccine (Oral Route) Revenue by Region (2018-2024) & (US$ Million)
Table 101. APAC Cholera Vaccine (Oral Route) Revenue by Region (2024-2034) & (US$ Million)
Table 102. APAC Cholera Vaccine (Oral Route) Sales Quantity by Region (2018-2024) & (K Units)
Table 103. APAC Cholera Vaccine (Oral Route) Sales Quantity by Region (2024-2034) & (K Units)
Table 104. Middle East, Africa and Latin America Cholera Vaccine (Oral Route) Sales Quantity by Company (2018-2024) & (K Units)
Table 105. Middle East, Africa and Latin America Cholera Vaccine (Oral Route) Revenue by Company (2018-2024) & (US$ Million)
Table 106. Middle East, Africa and Latin America Cholera Vaccine (Oral Route) Sales Quantity by Type (2018-2024) & (K Units)
Table 107. Middle East, Africa and Latin America Cholera Vaccine (Oral Route) Sales Quantity by Type (2024-2034) & (K Units)
Table 108. Middle East, Africa and Latin America Cholera Vaccine (Oral Route) Revenue by Type (2018-2024) & (US$ Million)
Table 109. Middle East, Africa and Latin America Cholera Vaccine (Oral Route) Revenue by Type (2024-2034) & (US$ Million)
Table 110. Middle East, Africa and Latin America Cholera Vaccine (Oral Route) Sales Quantity by Application (2018-2024) & (K Units)
Table 111. Middle East, Africa and Latin America Cholera Vaccine (Oral Route) Sales Quantity by Application (2024-2034) & (K Units)
Table 112. Middle East, Africa and Latin America Cholera Vaccine (Oral Route) Revenue by Application (2018-2024) & (US$ Million)
Table 113. Middle East, Africa and Latin America Cholera Vaccine (Oral Route) Revenue by Application (2024-2034) & (US$ Million)
Table 114. Middle East, Africa and Latin America Cholera Vaccine (Oral Route) Revenue by Country: 2018 VS 2022 VS 2034 (US$ Million)
Table 115. Middle East, Africa and Latin America Cholera Vaccine (Oral Route) Revenue by Country (2018-2024) & (US$ Million)
Table 116. Middle East, Africa and Latin America Cholera Vaccine (Oral Route) Revenue by Country (2024-2034) & (US$ Million)
Table 117. Middle East, Africa and Latin America Cholera Vaccine (Oral Route) Sales Quantity by Country (2018-2024) & (K Units)
Table 118. Middle East, Africa and Latin America Cholera Vaccine (Oral Route) Sales Quantity by Country (2024-2034) & (K Units)
Table 119. PaxVax Company Information
Table 120. PaxVax Description and Overview
Table 121. PaxVax Cholera Vaccine (Oral Route) Sales Quantity (K Units), Revenue (US$ Million), Average Selling Price (ASP) (USD/Unit) and Gross Margin (2018-2024)
Table 122. PaxVax Cholera Vaccine (Oral Route) Product and Services
Table 123. PaxVax Cholera Vaccine (Oral Route) SWOT Analysis
Table 124. PaxVax Recent Developments
Table 125. Sanofi Company Information
Table 126. Sanofi Description and Overview
Table 127. Sanofi Cholera Vaccine (Oral Route) Sales Quantity (K Units), Revenue (US$ Million), Average Selling Price (ASP) (USD/Unit) and Gross Margin (2018-2024)
Table 128. Sanofi Cholera Vaccine (Oral Route) Product and Services
Table 129. Sanofi Cholera Vaccine (Oral Route) SWOT Analysis
Table 130. Sanofi Recent Developments
Table 131. Valneva Company Information
Table 132. Valneva Description and Overview
Table 133. Valneva Cholera Vaccine (Oral Route) Sales Quantity (K Units), Revenue (US$ Million), Average Selling Price (ASP) (USD/Unit) and Gross Margin (2018-2024)
Table 134. Valneva Cholera Vaccine (Oral Route) Product and Services
Table 135. Valneva Cholera Vaccine (Oral Route) SWOT Analysis
Table 136. Valneva Recent Developments
Table 137. EuBiologics Company Information
Table 138. EuBiologics Description and Overview
Table 139. EuBiologics Cholera Vaccine (Oral Route) Sales Quantity (K Units), Revenue (US$ Million), Average Selling Price (ASP) (USD/Unit) and Gross Margin (2018-2024)
Table 140. EuBiologics Cholera Vaccine (Oral Route) Product and Services
Table 141. EuBiologics Cholera Vaccine (Oral Route) SWOT Analysis
Table 142. EuBiologics Recent Developments
Table 143. Key Raw Materials Lists
Table 144. Raw Materials Key Suppliers Lists
Table 145. Cholera Vaccine (Oral Route) Distributors List
Table 146. Cholera Vaccine (Oral Route) Customers List
Table 147. Cholera Vaccine (Oral Route) Market Trends
Table 148. Cholera Vaccine (Oral Route) Market Drivers
Table 149. Cholera Vaccine (Oral Route) Market Challenges
Table 150. Cholera Vaccine (Oral Route) Market Restraints
Table 151. Research Programs/Design for This Report
Table 152. Key Data Information from Secondary Sources
Table 153. Key Data Information from Primary Sources
List of Figures
Figure 1. Cholera Vaccine (Oral Route) Product Picture
Figure 2. Global Cholera Vaccine (Oral Route) Market Size Growth Rate by Type, 2018 VS 2022 VS 2034 (US$ Million)
Figure 3. Global Cholera Vaccine (Oral Route) Market Share by Type in 2022 & 2034
Figure 4. Shanchol Product Picture
Figure 5. Dukoral Product Picture
Figure 6. Vaxchora Product Picture
Figure 7. Others Product Picture
Figure 8. Global Cholera Vaccine (Oral Route) Market Size Growth Rate by Application, 2018 VS 2022 VS 2034 (US$ Million)
Figure 9. Global Cholera Vaccine (Oral Route) Market Share by Application in 2022 & 2034
Figure 10. Hospital
Figure 11. Research & Academic Laboratories
Figure 12. Pharmaceutical & Biotechnology Companies
Figure 13. Others
Figure 14. Cholera Vaccine (Oral Route) Report Years Considered
Figure 15. Global Cholera Vaccine (Oral Route) Revenue, (US$ Million), 2018 VS 2022 VS 2034
Figure 16. Global Cholera Vaccine (Oral Route) Revenue 2018-2034 (US$ Million)
Figure 17. Global Cholera Vaccine (Oral Route) Revenue Market Share by Region in Percentage: 2022 Versus 2034
Figure 18. Global Cholera Vaccine (Oral Route) Sales Quantity 2018-2034 (K Units)
Figure 19. Global Cholera Vaccine (Oral Route) Sales Quantity Market Share by Region (2018-2024)
Figure 20. Global Cholera Vaccine (Oral Route) Sales Quantity Market Share by Region (2024-2034)
Figure 21. North America Cholera Vaccine (Oral Route) Sales Quantity YoY (2018-2034) & (K Units)
Figure 22. North America Cholera Vaccine (Oral Route) Revenue YoY (2018-2034) & (US$ Million)
Figure 23. Europe Cholera Vaccine (Oral Route) Sales Quantity YoY (2018-2034) & (K Units)
Figure 24. Europe Cholera Vaccine (Oral Route) Revenue YoY (2018-2034) & (US$ Million)
Figure 25. China Cholera Vaccine (Oral Route) Sales Quantity YoY (2018-2034) & (K Units)
Figure 26. China Cholera Vaccine (Oral Route) Revenue YoY (2018-2034) & (US$ Million)
Figure 27. APAC Cholera Vaccine (Oral Route) Sales Quantity YoY (2018-2034) & (K Units)
Figure 28. APAC Cholera Vaccine (Oral Route) Revenue YoY (2018-2034) & (US$ Million)
Figure 29. Middle East, Africa and Latin America Cholera Vaccine (Oral Route) Sales Quantity YoY (2018-2034) & (K Units)
Figure 30. Middle East, Africa and Latin America Cholera Vaccine (Oral Route) Revenue YoY (2018-2034) & (US$ Million)
Figure 31. The Top 10 and Top 5 Players Market Share by Cholera Vaccine (Oral Route) Sales Quantity in 2022
Figure 32. The Top 10 and Top 5 Players Market Share by Cholera Vaccine (Oral Route) Revenue in 2022
Figure 33. Cholera Vaccine (Oral Route) Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2018 VS 2022
Figure 34. Global Cholera Vaccine (Oral Route) Sales Quantity Market Share by Type (2018-2034)
Figure 35. Global Cholera Vaccine (Oral Route) Revenue Market Share by Type (2018-2034)
Figure 36. Global Cholera Vaccine (Oral Route) Sales Quantity Market Share by Application (2018-2034)
Figure 37. Global Cholera Vaccine (Oral Route) Revenue Market Share by Application (2018-2034)
Figure 38. North America Cholera Vaccine (Oral Route) Revenue Market Share by Company in 2022
Figure 39. North America Cholera Vaccine (Oral Route) Sales Quantity Market Share by Company in 2022
Figure 40. North America Cholera Vaccine (Oral Route) Sales Quantity Market Share by Type (2018-2034)
Figure 41. North America Cholera Vaccine (Oral Route) Revenue Market Share by Type (2018-2034)
Figure 42. North America Cholera Vaccine (Oral Route) Sales Quantity Market Share by Application (2018-2034)
Figure 43. North America Cholera Vaccine (Oral Route) Revenue Market Share by Application (2018-2034)
Figure 44. North America Cholera Vaccine (Oral Route) Revenue Share by Country (2018-2034)
Figure 45. North America Cholera Vaccine (Oral Route) Sales Quantity Share by Country (2018-2034)
Figure 46. U.S. Cholera Vaccine (Oral Route) Revenue (2018-2034) & (US$ Million)
Figure 47. Canada Cholera Vaccine (Oral Route) Revenue (2018-2034) & (US$ Million)
Figure 48. Europe Cholera Vaccine (Oral Route) Sales Quantity Market Share by Company in 2022
Figure 49. Europe Cholera Vaccine (Oral Route) Revenue Market Share by Company in 2022
Figure 50. Europe Cholera Vaccine (Oral Route) Sales Quantity Market Share by Type (2018-2034)
Figure 51. Europe Cholera Vaccine (Oral Route) Revenue Market Share by Type (2018-2034)
Figure 52. Europe Cholera Vaccine (Oral Route) Sales Quantity Market Share by Application (2018-2034)
Figure 53. Europe Cholera Vaccine (Oral Route) Revenue Market Share by Application (2018-2034)
Figure 54. Europe Cholera Vaccine (Oral Route) Revenue Share by Country (2018-2034)
Figure 55. Europe Cholera Vaccine (Oral Route) Sales Quantity Share by Country (2018-2034)
Figure 56. Germany Cholera Vaccine (Oral Route) Revenue (2018-2034) & (US$ Million)
Figure 57. France Cholera Vaccine (Oral Route) Revenue (2018-2034) & (US$ Million)
Figure 58. U.K. Cholera Vaccine (Oral Route) Revenue (2018-2034) & (US$ Million)
Figure 59. Italy Cholera Vaccine (Oral Route) Revenue (2018-2034) & (US$ Million)
Figure 60. Russia Cholera Vaccine (Oral Route) Revenue (2018-2034) & (US$ Million)
Figure 61. China Cholera Vaccine (Oral Route) Sales Quantity Market Share by Company in 2022
Figure 62. China Cholera Vaccine (Oral Route) Revenue Market Share by Company in 2022
Figure 63. China Cholera Vaccine (Oral Route) Sales Quantity Market Share by Type (2018-2034)
Figure 64. China Cholera Vaccine (Oral Route) Revenue Market Share by Type (2018-2034)
Figure 65. China Cholera Vaccine (Oral Route) Sales Quantity Market Share by Application (2018-2034)
Figure 66. China Cholera Vaccine (Oral Route) Revenue Market Share by Application (2018-2034)
Figure 67. APAC Cholera Vaccine (Oral Route) Sales Quantity Market Share by Company in 2022
Figure 68. APAC Cholera Vaccine (Oral Route) Revenue Market Share by Company in 2022
Figure 69. APAC Cholera Vaccine (Oral Route) Sales Quantity Market Share by Type (2018-2034)
Figure 70. APAC Cholera Vaccine (Oral Route) Revenue Market Share by Type (2018-2034)
Figure 71. APAC Cholera Vaccine (Oral Route) Sales Quantity Market Share by Application (2018-2034)
Figure 72. APAC Cholera Vaccine (Oral Route) Revenue Market Share by Application (2018-2034)
Figure 73. APAC Cholera Vaccine (Oral Route) Revenue Share by Region (2018-2034)
Figure 74. APAC Cholera Vaccine (Oral Route) Sales Quantity Share by Region (2018-2034)
Figure 75. Japan Cholera Vaccine (Oral Route) Revenue (2018-2034) & (US$ Million)
Figure 76. South Korea Cholera Vaccine (Oral Route) Revenue (2018-2034) & (US$ Million)
Figure 77. China Taiwan Cholera Vaccine (Oral Route) Revenue (2018-2034) & (US$ Million)
Figure 78. Southeast Asia Cholera Vaccine (Oral Route) Revenue (2018-2034) & (US$ Million)
Figure 79. India Cholera Vaccine (Oral Route) Revenue (2018-2034) & (US$ Million)
Figure 80. Middle East, Africa and Latin America Cholera Vaccine (Oral Route) Sales Quantity Market Share by Company in 2022
Figure 81. Middle East, Africa and Latin America Cholera Vaccine (Oral Route) Revenue Market Share by Company in 2022
Figure 82. Middle East, Africa and Latin America Cholera Vaccine (Oral Route) Sales Quantity Market Share by Type (2018-2034)
Figure 83. Middle East, Africa and Latin America Cholera Vaccine (Oral Route) Revenue Market Share by Type (2018-2034)
Figure 84. Middle East, Africa and Latin America Cholera Vaccine (Oral Route) Sales Quantity Market Share by Application (2018-2034)
Figure 85. Middle East, Africa and Latin America Cholera Vaccine (Oral Route) Revenue Market Share by Application (2018-2034)
Figure 86. Middle East, Africa and Latin America Cholera Vaccine (Oral Route) Sales Quantity Share by Country (2018-2034)
Figure 87. Middle East, Africa and Latin America Cholera Vaccine (Oral Route) Revenue Share by Country (2018-2034)
Figure 88. Brazil Cholera Vaccine (Oral Route) Revenue (2018-2034) & (US$ Million)
Figure 89. Mexico Cholera Vaccine (Oral Route) Revenue (2018-2034) & (US$ Million)
Figure 90. Turkey Cholera Vaccine (Oral Route) Revenue (2018-2034) & (US$ Million)
Figure 91. Israel Cholera Vaccine (Oral Route) Revenue (2018-2034) & (US$ Million)
Figure 92. GCC Countries Cholera Vaccine (Oral Route) Revenue (2018-2034) & (US$ Million)
Figure 93. Cholera Vaccine (Oral Route) Value Chain
Figure 94. Cholera Vaccine (Oral Route) Production Process
Figure 95. Channels of Distribution (Direct Vs Distribution)
Figure 96. Distributors Profiles
Figure 97. Bottom-up and Top-down Approaches for This Report
Figure 98. Data Triangulation
Figure 99. Key Executives Interviewed